Identification

Name
Torasemide
Accession Number
DB00214  (APRD00295, APRD00217)
Type
Small Molecule
Groups
Approved
Description

Torasemide (rINN) or torsemide (USAN) is a pyridine-sulfonylurea type loop diuretic mainly used in the management of edema associated with congestive heart failure. It is also used at low doses for the management of hypertension. It is marketed under the brand name Demadex. [Wikipedia]

Structure
Thumb
Synonyms
  • 1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea
  • Luprac
  • N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide
  • Torasemida
  • Torasemidum
  • Torsemide
External IDs
AC-4464 / AC4464 / BM02.015
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DemadexTablet10 mg/1OralMeda Pharmaceuticals Ltd2015-01-012019-06-30Us
DemadexTablet100 mg/1OralMeda Pharmaceuticals Ltd2009-02-202016-01-20Us
DemadexTablet20 mg/1OralMeda Pharmaceuticals Ltd2009-02-202016-01-20Us
DemadexTablet5 mg/1OralMeda Pharmaceuticals Ltd2015-01-01Not applicableUs
DemadexTablet5 mg/1OralMeda Pharmaceuticals Ltd2009-02-202016-01-20Us
DemadexTablet100 mg/1OralMeda Pharmaceuticals Ltd2015-01-01Not applicableUs
DemadexTablet10 mg/1OralPhysicians Total Care, Inc.2000-11-28Not applicableUs
DemadexTablet10 mg/1OralMeda Pharmaceuticals Ltd2009-02-202016-01-20Us
DemadexTablet20 mg/1OralMeda Pharmaceuticals Ltd2015-01-012018-11-30Us
DemadexTablet20 mg/1OralPhysicians Total Care, Inc.2009-10-21Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TorsemideTablet100 mg/1OralCarilion Materials Management2011-01-01Not applicableUs
TorsemideTablet5 mg/1OralCitron Pharma LLC2007-10-17Not applicableUs
TorsemideInjection, solution10 mg/mLIntravenousAmerican Regent2010-05-26Not applicableUs
TorsemideTablet5 mg/1OralPar Pharmaceutical2009-01-272016-10-13Us
TorsemideTablet5 mg/1OralApotex Corporation2005-06-06Not applicableUs
TorsemideTablet10 mg/1Oralbryant ranch prepack2011-01-01Not applicableUs
TorsemideTablet5 mg/1OralAurobindo Pharma2007-10-17Not applicableUs
TorsemideTablet5 mg/1OralAv Pak2014-10-07Not applicableUs
TorsemideTablet10 mg/1OralAv Kare, Inc.2017-04-03Not applicableUs
TorsemideTablet5 mg/1OralQualitest2011-03-222016-11-08Us
International/Other Brands
Demadex / Diuver / Examide / Luprac
Categories
UNII
W31X2H97FB
CAS number
56211-40-6
Weight
Average: 348.42
Monoisotopic: 348.125611216
Chemical Formula
C16H20N4O3S
InChI Key
NGBFQHCMQULJNZ-UHFFFAOYSA-N
InChI
InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)
IUPAC Name
1-({4-[(3-methylphenyl)amino]pyridin-3-yl}sulfonyl)-3-(propan-2-yl)urea
SMILES
CC(C)NC(=O)NS(=O)(=O)C1=C(NC2=CC=CC(C)=C2)C=CN=C1

Pharmacology

Indication

For the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Also for the treatment of hypertension alone or in combination with other antihypertensive agents.

Structured Indications
Pharmacodynamics

Torasemide (INN) or torsemide (USAN) is a novel loop diuretic belonging to pridine sulphonyl urea. It differs form other thiazide diuretics in that a double ring system is incorporated into its structure. Like thiazides, loop diuretics must be secreted into the tubular fluid by proximal tubule cells. In the thick ascending loop Na+ and Cl- reabsorption is accomplished by a Na+/K+/2Cl- symporter. The thick ascending limb has a high reabsorptive capacity and is responsible for reabsorbing 25% of the filtered load of Na+. The loop diuretics act by blocking this symporter. Because of the large absorptive capacity and the amount of Na+ delivered to the ascending limb, loop diuretics have a profound diuretic action. In addition, more distal nephron segments do not have the reabsorptive capacity to compensate for this increased load. The osmotic gradient for water reabsorption is also reduced resulting in an increase in the amount of water excreted.

Mechanism of action

Torasemide inhibits the Na+/K+/2Cl--carrier system (via interference of the chloride binding site) in the lumen of the thick ascending portion of the loop of Henle, resulting in a decrease in reabsorption of sodium and chloride. This results in an increase in the rate of delivery of tubular fluid and electrolytes to the distal sites of hydrogen and potassium ion secretion, while plasma volume contraction increases aldosterone production. The increased delivery and high aldosterone levels promote sodium reabsorption at the distal tubules, and By increasing the delivery of sodium to the distal renal tubule, torasemide indirectly increases potassium excretion via the sodium-potassium exchange mechanism. Torasemide's effects in other segments of the nephron have not been demonstrated. Thus torasemide increases the urinary excretion of sodium, chloride, and water, but it does not significantly alter glomerular filtration rate, renal plasma flow, or acid-base balance. Torasemide's effects as a antihypertensive are due to its diuretic actions. By reducing extracellular and plasma fluid volume, blood pressure is reduced temporarily, and cardiac output also decreases.

TargetActionsOrganism
ASolute carrier family 12 member 1
inhibitor
Human
Absorption

Rapidly absorbed following oral administration. Absolute bioavailability is 80%. Food has no effect on absorption.

Volume of distribution
  • 12 to 15 L [normal adults or in patients with mild to moderate renal failure or congestive heart failure]
Protein binding

> 99%

Metabolism

Metabolized via the hepatic CYP2C8 to 5 metabolites. The major metabolite, M5, is pharmacologically inactive. There are 2 minor metabolites, M1, possessing one-tenth the activity of torasemide, and M3, equal in activity to torasemide. Overall, torasemide appears to account for 80% of the total diuretic activity, while metabolites M1 and M3 account for 9% and 11%, respectively.

Route of elimination

Torsemide is cleared from the circulation by both hepatic metabolism (approximately 80% of total clearance) and excretion into the urine (approximately 20% of total clearance in patients with normal renal function).

Half life

3.5 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include dehydration, hypovolemia, hypotension, hyponatremia, hypokalemia, hypochloremic alkalosis, and hemoconcentration. Oral LD50 in rat is 5 g/kg, and intravenous LD50 in rat is 500 mg/kg.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Torsemide Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Torasemide.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Torasemide.Experimental, Illicit
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Torasemide.Investigational
5-androstenedione5-androstenedione may increase the hypokalemic activities of Torasemide.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Torasemide.Experimental
AbirateroneThe serum concentration of Torasemide can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Torasemide.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Torasemide is combined with Acebutolol.Approved
AceclofenacAceclofenac may decrease the diuretic activities of Torasemide.Approved, Investigational
AcemetacinAcemetacin may decrease the diuretic activities of Torasemide.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Torasemide.Investigational, Withdrawn
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Torasemide is combined with Acetyldigitoxin.Approved
AcetyldigoxinThe risk or severity of adverse effects can be increased when Torasemide is combined with Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the diuretic activities of Torasemide.Approved, Vet Approved
AclarubicinThe risk or severity of adverse effects can be increased when Torasemide is combined with Aclarubicin.Investigational
AdapaleneAdapalene may decrease the diuretic activities of Torasemide.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Torasemide.Experimental, Investigational
AlclofenacAlclofenac may decrease the diuretic activities of Torasemide.Approved, Withdrawn
AlclometasoneAlclometasone may increase the hypokalemic activities of Torasemide.Approved
AlcuroniumTorasemide may decrease the neuromuscular blocking activities of Alcuronium.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Torasemide.Approved
AldosteroneAldosterone may increase the hypokalemic activities of Torasemide.Experimental, Investigational
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Torasemide.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Torasemide.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Torasemide is combined with Aliskiren.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Torasemide.Investigational
AllopurinolThe risk or severity of adverse effects can be increased when Torasemide is combined with Allopurinol.Approved
AlminoprofenAlminoprofen may decrease the diuretic activities of Torasemide.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Torasemide.Approved
AloxiprinAloxiprin may decrease the diuretic activities of Torasemide.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Torasemide.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Torasemide.Illicit
AlprenololTorasemide may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanTorasemide may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmcinonideAmcinonide may increase the hypokalemic activities of Torasemide.Approved
AmifostineTorasemide may increase the hypotensive activities of Amifostine.Approved, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Torasemide is combined with Amikacin.Approved, Vet Approved
AmilorideThe risk or severity of adverse effects can be increased when Torasemide is combined with Amiloride.Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the diuretic activities of Torasemide.Approved
AmiodaroneThe metabolism of Torasemide can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Torasemide is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Torasemide.Approved, Illicit
AmphetamineAmphetamine may increase the hypotensive activities of Torasemide.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Torasemide.Approved, Investigational
AmrubicinThe risk or severity of adverse effects can be increased when Torasemide is combined with Amrubicin.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Torasemide is combined with Amyl Nitrite.Approved
AndrographolideAndrographolide may decrease the diuretic activities of Torasemide.Investigational
AndrostenedioneAndrostenedione may increase the hypokalemic activities of Torasemide.Experimental, Illicit
AnecortaveAnecortave may increase the hypokalemic activities of Torasemide.Investigational
anecortave acetateanecortave acetate may increase the hypokalemic activities of Torasemide.Investigational
AnisodamineAnisodamine may decrease the diuretic activities of Torasemide.Investigational
annamycinThe risk or severity of adverse effects can be increased when Torasemide is combined with annamycin.Investigational
AntipyrineAntipyrine may decrease the diuretic activities of Torasemide.Approved
ApocyninApocynin may decrease the diuretic activities of Torasemide.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Torasemide.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Torasemide is combined with Apraclonidine.Approved
ApramycinThe risk or severity of adverse effects can be increased when Torasemide is combined with Apramycin.Experimental, Vet Approved
ApremilastApremilast may decrease the diuretic activities of Torasemide.Approved, Investigational
AprepitantThe metabolism of Torasemide can be increased when combined with Aprepitant.Approved, Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Torasemide is combined with Arbekacin.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Torasemide.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Torasemide.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Torasemide.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Torasemide.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Torasemide.Approved, Investigational
AtamestaneAtamestane may increase the hypokalemic activities of Torasemide.Investigational
AtenololThe risk or severity of adverse effects can be increased when Torasemide is combined with Atenolol.Approved
AtracuriumTorasemide may decrease the neuromuscular blocking activities of Atracurium.Experimental, Investigational
Atracurium besylateTorasemide may decrease the neuromuscular blocking activities of Atracurium besylate.Approved
AvanafilAvanafil may increase the antihypertensive activities of Torasemide.Approved
AzapropazoneAzapropazone may decrease the diuretic activities of Torasemide.Withdrawn
AzelastineAzelastine may decrease the diuretic activities of Torasemide.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Torasemide is combined with Azilsartan medoxomil.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Torasemide.Investigational
BalsalazideBalsalazide may decrease the diuretic activities of Torasemide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Torasemide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Torasemide.Experimental
BarbitalBarbital may increase the hypotensive activities of Torasemide.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Torasemide.Approved
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Torasemide.Approved, Investigational
BekanamycinThe risk or severity of adverse effects can be increased when Torasemide is combined with Bekanamycin.Experimental
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Torasemide.Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Torasemide is combined with Benazepril.Approved, Investigational
BendazacBendazac may decrease the diuretic activities of Torasemide.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Torasemide is combined with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Torasemide.Withdrawn
BenorilateBenorilate may decrease the diuretic activities of Torasemide.Experimental
BenoxaprofenBenoxaprofen may decrease the diuretic activities of Torasemide.Withdrawn
BenzydamineBenzydamine may decrease the diuretic activities of Torasemide.Approved
BepridilTorasemide may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneBetamethasone may increase the hypokalemic activities of Torasemide.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Torasemide.Approved
BethanidineBethanidine may increase the hypotensive activities of Torasemide.Approved
BevoniumBevonium may decrease the diuretic activities of Torasemide.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Torasemide.Experimental, Illicit, Withdrawn
BietaserpineBietaserpine may increase the hypotensive activities of Torasemide.Experimental
BimatoprostTorasemide may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Torasemide is combined with Bisoprolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Torasemide.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Torasemide.Approved, Investigational
BQ-123Torasemide may increase the hypotensive activities of BQ-123.Investigational
BretyliumThe risk or severity of adverse effects can be increased when Torasemide is combined with Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Torasemide.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Torasemide.Experimental
BromfenacBromfenac may decrease the diuretic activities of Torasemide.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Torasemide.Approved, Investigational
BucillamineBucillamine may decrease the diuretic activities of Torasemide.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Torasemide.Approved
BufexamacBufexamac may decrease the diuretic activities of Torasemide.Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Torasemide.Investigational, Withdrawn
BumadizoneBumadizone may decrease the diuretic activities of Torasemide.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Torasemide is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Torasemide.Approved, Investigational
BupranololTorasemide may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Torasemide.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Torasemide.Approved, Illicit, Vet Approved
CadralazineCadralazine may increase the hypotensive activities of Torasemide.Experimental
CafedrineTorasemide may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinCanagliflozin may increase the hypotensive activities of Torasemide.Approved
CandesartanTorasemide may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Torasemide is combined with Candesartan cilexetil.Approved
CandoxatrilTorasemide may increase the hypotensive activities of Candoxatril.Experimental
CapecitabineThe metabolism of Torasemide can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Torasemide is combined with Captopril.Approved
CarbamazepineThe metabolism of Torasemide can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may decrease the diuretic activities of Torasemide.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Torasemide.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Torasemide.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Torasemide.Illicit, Investigational, Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Torasemide.Withdrawn
CarprofenCarprofen may decrease the diuretic activities of Torasemide.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Torasemide is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Torasemide is combined with Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the diuretic activities of Torasemide.Experimental
CelecoxibCelecoxib may decrease the diuretic activities of Torasemide.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Torasemide.Approved, Investigational
CeritinibThe serum concentration of Torasemide can be increased when it is combined with Ceritinib.Approved
ChloroquineChloroquine may decrease the diuretic activities of Torasemide.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Torasemide is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Torasemide.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Torasemide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Torasemide is combined with Chlorthalidone.Approved
CholecalciferolThe metabolism of Torasemide can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Torasemide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the diuretic activities of Torasemide.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Torasemide.Approved, Investigational
CicletanineTorasemide may increase the hypotensive activities of Cicletanine.Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Torasemide.Experimental
CilazaprilThe risk or severity of adverse effects can be increased when Torasemide is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Torasemide.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Torasemide.Approved
CisatracuriumTorasemide may decrease the neuromuscular blocking activities of Cisatracurium.Approved, Experimental
Cisatracurium besylateTorasemide may decrease the neuromuscular blocking activities of Cisatracurium besylate.Approved
CisplatinTorasemide may increase the nephrotoxic activities of Cisplatin.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Torasemide.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Torasemide is combined with Clevidipine.Approved
ClobetasolClobetasol may increase the hypokalemic activities of Torasemide.Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Torasemide.Approved
ClobetasoneClobetasone may increase the hypokalemic activities of Torasemide.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Torasemide.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Torasemide.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Torasemide.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Torasemide is combined with Clonidine.Approved
ClonixinClonixin may decrease the diuretic activities of Torasemide.Approved
CloranololTorasemide may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Torasemide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Torasemide.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Torasemide.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Torasemide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Torasemide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Torasemide.Approved, Investigational
Cortexolone 17α-propionateCortexolone 17α-propionate may increase the hypokalemic activities of Torasemide.Investigational
CorticosteroneCorticosterone may increase the hypokalemic activities of Torasemide.Experimental
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Torasemide.Approved
CrisaboroleThe metabolism of Torasemide can be decreased when combined with Crisaborole.Approved
CryptenamineTorasemide may increase the hypotensive activities of Cryptenamine.Approved
CurcuminCurcumin may decrease the diuretic activities of Torasemide.Investigational
CyclopenthiazideTorasemide may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Torasemide.Approved, Investigational, Vet Approved
CyclothiazideTorasemide may increase the hypotensive activities of Cyclothiazide.Approved
CymarinThe risk or severity of adverse effects can be increased when Torasemide is combined with Cymarin.Experimental
D-LimoneneD-Limonene may decrease the diuretic activities of Torasemide.Investigational
DabrafenibThe serum concentration of Torasemide can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Torasemide is combined with Dapagliflozin.Approved
DaunorubicinThe risk or severity of adverse effects can be increased when Torasemide is combined with Daunorubicin.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Torasemide.Approved, Investigational
DecamethoniumTorasemide may decrease the neuromuscular blocking activities of Decamethonium.Approved
DeferasiroxThe serum concentration of Torasemide can be increased when it is combined with Deferasirox.Approved, Investigational
DeflazacortDeflazacort may increase the hypokalemic activities of Torasemide.Approved
DelaprilTorasemide may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe metabolism of Torasemide can be decreased when combined with Delavirdine.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Torasemide.Investigational
dersalazinedersalazine may decrease the diuretic activities of Torasemide.Investigational
DeserpidineTorasemide may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Torasemide.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Torasemide is combined with Deslanoside.Approved
DesonideDesonide may increase the hypokalemic activities of Torasemide.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Torasemide.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Torasemide.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Torasemide.Experimental, Vet Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Torasemide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Torasemide.Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Torasemide is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Torasemide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Torasemide.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Torasemide.Approved, Investigational
DiazoxideDiazoxide may increase the hypotensive activities of Torasemide.Approved
DibekacinThe risk or severity of adverse effects can be increased when Torasemide is combined with Dibekacin.Experimental
DiclofenacDiclofenac may decrease the diuretic activities of Torasemide.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Torasemide is combined with Diclofenamide.Approved
diethylnorspermineTorasemide may increase the hypotensive activities of diethylnorspermine.Investigational
DifenpiramideDifenpiramide may decrease the diuretic activities of Torasemide.Experimental
DiflorasoneDiflorasone may increase the hypokalemic activities of Torasemide.Approved
DiflunisalDiflunisal may decrease the diuretic activities of Torasemide.Approved
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Torasemide.Approved, Investigational
DifluprednateDifluprednate may increase the hypokalemic activities of Torasemide.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Torasemide is combined with Digitoxin.Approved, Investigational
DigoxinThe risk or severity of adverse effects can be increased when Torasemide is combined with Digoxin.Approved
Digoxin Immune Fab (Ovine)The risk or severity of adverse effects can be increased when Torasemide is combined with Digoxin Immune Fab (Ovine).Approved
DihydralazineDihydralazine may increase the hypotensive activities of Torasemide.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Torasemide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Torasemide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Torasemide.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Torasemide is combined with Dihydrostreptomycin.Investigational, Vet Approved
DiltiazemThe risk or severity of adverse effects can be increased when Torasemide is combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Torasemide is combined with Dinutuximab.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Torasemide.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Torasemide.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Torasemide is combined with Dipyridamole.Approved
DobutamineDobutamine may increase the hypokalemic activities of Torasemide.Approved
DofetilideTorasemide may increase the QTc-prolonging activities of Dofetilide.Approved
Domoic AcidTorasemide may decrease the neuromuscular blocking activities of Domoic Acid.Experimental
DorzolamideTorasemide may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe metabolism of Torasemide can be decreased when combined with Dosulepin.Approved
Doxacurium chlorideTorasemide may decrease the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Torasemide is combined with Doxazosin.Approved
DoxorubicinThe risk or severity of adverse effects can be increased when Torasemide is combined with Doxorubicin.Approved, Investigational
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Torasemide.Experimental
DroxicamDroxicam may decrease the diuretic activities of Torasemide.Approved
DroxidopaDroxidopa may increase the hypokalemic activities of Torasemide.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Torasemide.Approved
DuloxetineTorasemide may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the diuretic activities of Torasemide.Investigational
E-6201E-6201 may decrease the diuretic activities of Torasemide.Investigational
EfavirenzThe metabolism of Torasemide can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineTorasemide may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Torasemide is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Torasemide is combined with Enalapril.Approved, Vet Approved
EnalaprilatTorasemide may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Torasemide.Experimental
EpanololTorasemide may increase the hypotensive activities of Epanolol.Experimental
EphedraEphedra may increase the hypokalemic activities of Torasemide.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Torasemide.Approved, Vet Approved
EpirizoleEpirizole may decrease the diuretic activities of Torasemide.Approved
EpirubicinThe risk or severity of adverse effects can be increased when Torasemide is combined with Epirubicin.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Torasemide is combined with Eplerenone.Approved
EpoprostenolTorasemide may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Torasemide is combined with Eprosartan.Approved
EquileninEquilenin may increase the hypokalemic activities of Torasemide.Experimental
EquilinEquilin may increase the hypokalemic activities of Torasemide.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Torasemide.Approved
EstroneEstrone may increase the hypokalemic activities of Torasemide.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Torasemide.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Torasemide is combined with Etacrynic acid.Approved
EtanerceptEtanercept may decrease the diuretic activities of Torasemide.Approved, Investigational
EthenzamideEthenzamide may decrease the diuretic activities of Torasemide.Experimental
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Torasemide.Approved, Illicit
EtodolacEtodolac may decrease the diuretic activities of Torasemide.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the diuretic activities of Torasemide.Approved, Investigational
EtoricoxibEtoricoxib may decrease the diuretic activities of Torasemide.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Torasemide.Illicit, Vet Approved
EtravirineThe metabolism of Torasemide can be decreased when combined with Etravirine.Approved
Evening primrose oilEvening primrose oil may decrease the diuretic activities of Torasemide.Approved, Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Torasemide.Approved, Investigational
exisulindexisulind may decrease the diuretic activities of Torasemide.Investigational
FelbinacFelbinac may decrease the diuretic activities of Torasemide.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Torasemide is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the diuretic activities of Torasemide.Approved
FenoldopamTorasemide may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenFenoprofen may decrease the diuretic activities of Torasemide.Approved
FenoterolFenoterol may increase the hypokalemic activities of Torasemide.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Torasemide.Approved, Illicit, Investigational, Vet Approved
FentiazacFentiazac may decrease the diuretic activities of Torasemide.Experimental
FeprazoneFeprazone may decrease the diuretic activities of Torasemide.Experimental
Ferulic acidFerulic acid may decrease the diuretic activities of Torasemide.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Torasemide.Approved, Investigational
FloctafenineFloctafenine may decrease the diuretic activities of Torasemide.Approved, Withdrawn
FloxuridineThe metabolism of Torasemide can be decreased when combined with Floxuridine.Approved
fluasteronefluasterone may increase the hypokalemic activities of Torasemide.Investigational
FluconazoleThe metabolism of Torasemide can be decreased when combined with Fluconazole.Approved
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Torasemide.Approved
FlumethasoneFlumethasone may increase the hypokalemic activities of Torasemide.Approved, Vet Approved
FlunisolideFlunisolide may increase the hypokalemic activities of Torasemide.Approved, Investigational
FlunixinFlunixin may decrease the diuretic activities of Torasemide.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the diuretic activities of Torasemide.Experimental
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Torasemide.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Torasemide.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Torasemide.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Torasemide.Approved
FluorouracilThe metabolism of Torasemide can be decreased when combined with Fluorouracil.Approved
FluprednideneFluprednidene may increase the hypokalemic activities of Torasemide.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Torasemide.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Torasemide.Approved
FlurbiprofenFlurbiprofen may decrease the diuretic activities of Torasemide.Approved, Investigational
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Torasemide.Approved
Fluticasone propionateFluticasone propionate may increase the hypokalemic activities of Torasemide.Approved
FluvastatinThe metabolism of Torasemide can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Torasemide can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneFormestane may increase the hypokalemic activities of Torasemide.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Torasemide.Approved, Investigational
FoscarnetThe serum concentration of Foscarnet can be increased when it is combined with Torasemide.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Torasemide is combined with Fosinopril.Approved
FosphenytoinFosphenytoin may decrease the diuretic activities of Torasemide.Approved
FramycetinThe risk or severity of adverse effects can be increased when Torasemide is combined with Framycetin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Torasemide.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Furosemide.Approved, Vet Approved
GallamineTorasemide may decrease the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideTorasemide may decrease the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GemfibrozilThe metabolism of Torasemide can be decreased when combined with Gemfibrozil.Approved
GeneticinThe risk or severity of adverse effects can be increased when Torasemide is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Torasemide is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Torasemide is combined with GENTAMICIN C1A.Experimental
GitoformateThe risk or severity of adverse effects can be increased when Torasemide is combined with Gitoformate.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Torasemide.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Torasemide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Torasemide.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Torasemide.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Torasemide.Approved, Investigational
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Torasemide.Approved
GPX-150The risk or severity of adverse effects can be increased when Torasemide is combined with GPX-150.Investigational
GuacetisalGuacetisal may decrease the diuretic activities of Torasemide.Experimental
GuanabenzTorasemide may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelTorasemide may increase the hypotensive activities of Guanadrel.Approved
GuanazodineTorasemide may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineTorasemide may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Torasemide is combined with Guanfacine.Approved, Investigational
GuanoclorTorasemide may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzTorasemide may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanTorasemide may increase the hypotensive activities of Guanoxan.Experimental
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Torasemide.Investigational
HalcinonideHalcinonide may increase the hypokalemic activities of Torasemide.Approved, Investigational, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Torasemide.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Torasemide.Experimental
HE3286HE3286 may increase the hypokalemic activities of Torasemide.Investigational
Hemoglobin crosfumarilHemoglobin crosfumaril may decrease the diuretic activities of Torasemide.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Torasemide.Approved, Illicit, Investigational
HexamethoniumTorasemide may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Torasemide.Approved
HigenamineHigenamine may decrease the diuretic activities of Torasemide.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Torasemide.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Torasemide is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Torasemide is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Torasemide.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Torasemide.Approved, Vet Approved
HydroflumethiazideTorasemide may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Torasemide.Approved, Illicit
Hygromycin BThe risk or severity of adverse effects can be increased when Torasemide is combined with Hygromycin B.Vet Approved
IbuprofenIbuprofen may decrease the diuretic activities of Torasemide.Approved
IbuproxamIbuproxam may decrease the diuretic activities of Torasemide.Withdrawn
IcatibantIcatibant may decrease the diuretic activities of Torasemide.Approved
IdarubicinThe risk or severity of adverse effects can be increased when Torasemide is combined with Idarubicin.Approved
IloprostIloprost may increase the hypotensive activities of Torasemide.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Torasemide.Investigational
Imidazole salicylateImidazole salicylate may decrease the diuretic activities of Torasemide.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Torasemide.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Torasemide.Approved
IndapamideThe risk or severity of adverse effects can be increased when Torasemide is combined with Indapamide.Approved
IndenololTorasemide may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Torasemide can be decreased when combined with Indinavir.Approved
IndobufenIndobufen may decrease the diuretic activities of Torasemide.Investigational
IndomethacinIndomethacin may decrease the diuretic activities of Torasemide.Approved, Investigational
IndoprofenIndoprofen may decrease the diuretic activities of Torasemide.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Torasemide.Withdrawn
INNO-206The risk or severity of adverse effects can be increased when Torasemide is combined with INNO-206.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Torasemide.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Torasemide.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Torasemide.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Torasemide.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Torasemide.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Torasemide.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Torasemide.Approved
IproclozideIproclozide may increase the hypotensive activities of Torasemide.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Torasemide.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Torasemide is combined with Irbesartan.Approved, Investigational
IsepamicinThe risk or severity of adverse effects can be increased when Torasemide is combined with Isepamicin.Experimental
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Torasemide.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Torasemide.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Torasemide.Approved, Vet Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Torasemide.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Torasemide is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Torasemide is combined with Isosorbide Mononitrate.Approved
IsoxicamIsoxicam may decrease the diuretic activities of Torasemide.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Torasemide is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Torasemide is combined with Isradipine.Approved
IstaroximeIstaroxime may increase the hypokalemic activities of Torasemide.Investigational
IvabradineTorasemide may increase the arrhythmogenic activities of Ivabradine.Approved
KanamycinThe risk or severity of adverse effects can be increased when Torasemide is combined with Kanamycin.Approved, Investigational, Vet Approved
KebuzoneKebuzone may decrease the diuretic activities of Torasemide.Experimental
KetanserinKetanserin may increase the hypotensive activities of Torasemide.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Torasemide.Approved, Investigational
KetoconazoleThe metabolism of Torasemide can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may decrease the diuretic activities of Torasemide.Approved, Vet Approved
KetorolacKetorolac may decrease the diuretic activities of Torasemide.Approved
LabetalolThe risk or severity of adverse effects can be increased when Torasemide is combined with Labetalol.Approved
LacidipineTorasemide may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanatoside CThe risk or severity of adverse effects can be increased when Torasemide is combined with Lanatoside C.Experimental
LapatinibThe metabolism of Torasemide can be decreased when combined with Lapatinib.Approved, Investigational
LatanoprostTorasemide may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideLeflunomide may decrease the diuretic activities of Torasemide.Approved, Investigational
LercanidipineTorasemide may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Torasemide is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Torasemide.Approved, Investigational
LevodopaTorasemide may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Torasemide.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Torasemide.Approved
LevosalbutamolLevosalbutamol may increase the hypokalemic activities of Torasemide.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Torasemide.Approved, Investigational
LicoriceLicorice may increase the hypokalemic activities of Torasemide.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Torasemide.Approved
LinsidomineTorasemide may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Torasemide.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Torasemide is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the diuretic activities of Torasemide.Investigational
LithiumThe serum concentration of Lithium can be decreased when it is combined with Torasemide.Approved
LobeglitazoneThe metabolism of Torasemide can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Torasemide.Illicit
LofexidineTorasemide may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacLonazolac may decrease the diuretic activities of Torasemide.Experimental
LornoxicamLornoxicam may decrease the diuretic activities of Torasemide.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Torasemide is combined with Losartan.Approved
LoteprednolLoteprednol may increase the hypokalemic activities of Torasemide.Approved
LovastatinThe metabolism of Torasemide can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenLoxoprofen may decrease the diuretic activities of Torasemide.Approved, Investigational
LumacaftorThe serum concentration of Torasemide can be increased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may decrease the diuretic activities of Torasemide.Approved, Investigational
MacitentanTorasemide may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the diuretic activities of Torasemide.Approved
ManidipineTorasemide may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Torasemide is combined with Mannitol.Approved, Investigational
MasoprocolMasoprocol may decrease the diuretic activities of Torasemide.Approved, Investigational
ME-609ME-609 may increase the hypokalemic activities of Torasemide.Investigational
MebanazineMebanazine may increase the hypotensive activities of Torasemide.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Torasemide is combined with Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the diuretic activities of Torasemide.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Torasemide.Approved
Mefenamic acidMefenamic acid may decrease the diuretic activities of Torasemide.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Torasemide.Vet Approved
MeloxicamMeloxicam may decrease the diuretic activities of Torasemide.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Torasemide.Experimental
MesalazineMesalazine may decrease the diuretic activities of Torasemide.Approved
MetamizoleMetamizole may decrease the diuretic activities of Torasemide.Investigational, Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Torasemide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Torasemide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Torasemide.Approved, Illicit
MethazolamideThe risk or severity of adverse effects can be increased when Torasemide is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Torasemide.Approved
MethoserpidineTorasemide may increase the hypotensive activities of Methoserpidine.Experimental
MethotrexateThe therapeutic efficacy of Torasemide can be decreased when used in combination with Methotrexate.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Torasemide is combined with Methyclothiazide.Approved
Methyl salicylateMethyl salicylate may decrease the diuretic activities of Torasemide.Approved, Vet Approved
MethyldopaThe risk or severity of adverse effects can be increased when Torasemide is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Torasemide.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Torasemide.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Torasemide.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Torasemide.Approved, Vet Approved
MetildigoxinThe risk or severity of adverse effects can be increased when Torasemide is combined with Metildigoxin.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Torasemide is combined with Metipranolol.Approved
MetocurineTorasemide may decrease the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideTorasemide may decrease the neuromuscular blocking activities of Metocurine Iodide.Withdrawn
MetolazoneThe risk or severity of adverse effects can be increased when Torasemide is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Torasemide is combined with Metoprolol.Approved, Investigational
MetrizamideThe risk or severity of adverse effects can be increased when Torasemide is combined with Metrizamide.Approved
MetyrosineTorasemide may increase the hypotensive activities of Metyrosine.Approved
MibefradilTorasemide may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MicronomicinThe risk or severity of adverse effects can be increased when Torasemide is combined with Micronomicin.Experimental
MidostaurinThe metabolism of Torasemide can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Torasemide can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Torasemide.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Torasemide.Approved
MinaprineMinaprine may increase the hypotensive activities of Torasemide.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Torasemide is combined with Minoxidil.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Torasemide.Investigational
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Torasemide.Approved, Investigational
MivacuriumTorasemide may decrease the neuromuscular blocking activities of Mivacurium.Approved
MizoribineMizoribine may decrease the diuretic activities of Torasemide.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Torasemide.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Torasemide is combined with Moexipril.Approved
MofebutazoneMofebutazone may decrease the diuretic activities of Torasemide.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Torasemide.Approved, Investigational
MometasoneMometasone may increase the hypokalemic activities of Torasemide.Approved, Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Torasemide.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Torasemide.Approved, Investigational
MuzolimineTorasemide may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the diuretic activities of Torasemide.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the diuretic activities of Torasemide.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Torasemide.Approved, Investigational
NabumetoneNabumetone may decrease the diuretic activities of Torasemide.Approved
NadololThe risk or severity of adverse effects can be increased when Torasemide is combined with Nadolol.Approved
NafamostatNafamostat may decrease the diuretic activities of Torasemide.Approved, Investigational
NaftifineNaftifine may decrease the diuretic activities of Torasemide.Approved
NaftopidilTorasemide may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Torasemide.Approved
NaproxenNaproxen may decrease the diuretic activities of Torasemide.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Torasemide.Approved, Investigational
NCX 1022NCX 1022 may increase the hypokalemic activities of Torasemide.Investigational
NeamineThe risk or severity of adverse effects can be increased when Torasemide is combined with Neamine.Experimental
NebivololThe risk or severity of adverse effects can be increased when Torasemide is combined with Nebivolol.Approved, Investigational
NeomycinThe risk or severity of adverse effects can be increased when Torasemide is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinTorasemide may decrease the neuromuscular blocking activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the diuretic activities of Torasemide.Approved
NesiritideThe risk or severity of adverse effects can be increased when Torasemide is combined with Nesiritide.Approved, Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Torasemide is combined with Netilmicin.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Torasemide.Withdrawn
NicardipineThe metabolism of Torasemide can be decreased when combined with Nicardipine.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Torasemide.Experimental
NicorandilNicorandil may increase the hypotensive activities of Torasemide.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Torasemide is combined with Nifedipine.Approved
NifenazoneNifenazone may decrease the diuretic activities of Torasemide.Experimental
Niflumic AcidNiflumic Acid may decrease the diuretic activities of Torasemide.Approved
NiguldipineTorasemide may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Torasemide can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineTorasemide may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideNimesulide may decrease the diuretic activities of Torasemide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Torasemide is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Torasemide is combined with Nisoldipine.Approved
NitrendipineTorasemide may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Torasemide.Approved
NitroaspirinNitroaspirin may decrease the diuretic activities of Torasemide.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Torasemide is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Torasemide is combined with Nitroprusside.Approved
NorepinephrineNorepinephrine may increase the hypokalemic activities of Torasemide.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Torasemide.Approved, Illicit
ObinutuzumabTorasemide may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Torasemide.Withdrawn
OleandrinThe risk or severity of adverse effects can be increased when Torasemide is combined with Oleandrin.Experimental, Investigational
Oleoyl-estroneOleoyl-estrone may increase the hypokalemic activities of Torasemide.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Torasemide is combined with Olmesartan.Approved, Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Torasemide.Approved
OlopatadineOlopatadine may decrease the diuretic activities of Torasemide.Approved
OlsalazineOlsalazine may decrease the diuretic activities of Torasemide.Approved
OmapatrilatTorasemide may increase the hypotensive activities of Omapatrilat.Investigational
OmeprazoleThe metabolism of Torasemide can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Torasemide.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Torasemide.Approved
OrgoteinOrgotein may decrease the diuretic activities of Torasemide.Vet Approved
OuabainThe risk or severity of adverse effects can be increased when Torasemide is combined with Ouabain.Approved
OxaprozinOxaprozin may decrease the diuretic activities of Torasemide.Approved
OxprenololTorasemide may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Torasemide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Torasemide.Approved, Investigational, Vet Approved
OxyphenbutazoneOxyphenbutazone may decrease the diuretic activities of Torasemide.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Torasemide.Approved, Vet Approved
PancuroniumTorasemide may decrease the neuromuscular blocking activities of Pancuronium.Approved
PapaverineThe risk or severity of adverse effects can be increased when Torasemide is combined with Papaverine.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Torasemide.Approved
ParecoxibParecoxib may decrease the diuretic activities of Torasemide.Approved
PargylinePargyline may increase the hypotensive activities of Torasemide.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Torasemide is combined with Paromomycin.Approved, Investigational
ParthenolideParthenolide may decrease the diuretic activities of Torasemide.Investigational
PenbutololThe risk or severity of adverse effects can be increased when Torasemide is combined with Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Torasemide.Approved, Vet Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Torasemide.Approved, Vet Approved
PentoliniumTorasemide may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Torasemide.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Torasemide is combined with Perindopril.Approved
PeruvosideThe risk or severity of adverse effects can be increased when Torasemide is combined with Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Torasemide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Torasemide.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Torasemide.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Torasemide.Approved, Investigational, Withdrawn
PheniprazinePheniprazine may increase the hypotensive activities of Torasemide.Withdrawn
PhenobarbitalThe metabolism of Torasemide can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Torasemide.Experimental
PhenoxybenzamineTorasemide may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Torasemide.Withdrawn
PhentolamineTorasemide may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the diuretic activities of Torasemide.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Torasemide.Approved, Vet Approved, Withdrawn
PhenytoinPhenytoin may decrease the diuretic activities of Torasemide.Approved, Vet Approved
PimecrolimusPimecrolimus may decrease the diuretic activities of Torasemide.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Torasemide.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Torasemide is combined with Pindolol.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Torasemide.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Torasemide.Approved, Investigational
PipecuroniumTorasemide may decrease the neuromuscular blocking activities of Pipecuronium.Approved
PirarubicinThe risk or severity of adverse effects can be increased when Torasemide is combined with Pirarubicin.Investigational
PirbuterolPirbuterol may increase the hypokalemic activities of Torasemide.Approved
PirfenidonePirfenidone may decrease the diuretic activities of Torasemide.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Torasemide.Investigational
PirlindolePirlindole may increase the hypotensive activities of Torasemide.Approved
PiroxicamPiroxicam may decrease the diuretic activities of Torasemide.Approved, Investigational
PirprofenPirprofen may decrease the diuretic activities of Torasemide.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Torasemide.Withdrawn
Platelet Activating FactorTorasemide may increase the hypotensive activities of Platelet Activating Factor.Experimental
PlazomicinThe risk or severity of adverse effects can be increased when Torasemide is combined with Plazomicin.Investigational
PlicamycinThe risk or severity of adverse effects can be increased when Torasemide is combined with Plicamycin.Approved, Investigational, Withdrawn
PolythiazideTorasemide may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Torasemide.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Torasemide.Approved, Investigational
PranoprofenPranoprofen may decrease the diuretic activities of Torasemide.Experimental, Investigational
PrasteronePrasterone may increase the hypokalemic activities of Torasemide.Approved, Nutraceutical
Prasterone sulfatePrasterone sulfate may increase the hypokalemic activities of Torasemide.Investigational
PrazosinThe risk or severity of adverse effects can be increased when Torasemide is combined with Prazosin.Approved
PrednicarbatePrednicarbate may increase the hypokalemic activities of Torasemide.Approved
PrednisolonePrednisolone may increase the hypokalemic activities of Torasemide.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Torasemide.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Torasemide.Experimental, Investigational
PrimidoneThe metabolism of Torasemide can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe risk or severity of adverse effects can be increased when Probenecid is combined with Torasemide.Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Torasemide.Approved
ProcaterolProcaterol may increase the hypokalemic activities of Torasemide.Approved, Investigational
ProglumetacinProglumetacin may decrease the diuretic activities of Torasemide.Experimental
PropacetamolPropacetamol may decrease the diuretic activities of Torasemide.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Torasemide.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Torasemide is combined with Propranolol.Approved, Investigational
PropyphenazonePropyphenazone may decrease the diuretic activities of Torasemide.Experimental
ProquazoneProquazone may decrease the diuretic activities of Torasemide.Experimental
ProscillaridinThe risk or severity of adverse effects can be increased when Torasemide is combined with Proscillaridin.Experimental
PTC299PTC299 may decrease the diuretic activities of Torasemide.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Torasemide is combined with Puromycin.Experimental
PyrantelTorasemide may decrease the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
PyrimethamineThe metabolism of Torasemide can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Torasemide is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Torasemide is combined with Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Torasemide.Approved
RabeprazoleThe metabolism of Torasemide can be decreased when combined with Rabeprazole.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Torasemide.Approved
RapacuroniumTorasemide may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Torasemide.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Torasemide.Approved
RemikirenRemikiren may increase the hypotensive activities of Torasemide.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Torasemide.Approved, Investigational
RescinnamineTorasemide may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Torasemide.Approved, Investigational
ResveratrolResveratrol may decrease the diuretic activities of Torasemide.Approved, Experimental, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Torasemide is combined with Ribostamycin.Approved, Investigational
RifampicinThe metabolism of Torasemide can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Torasemide can be increased when combined with Rifapentine.Approved
RilmenidineRilmenidine may increase the hypotensive activities of Torasemide.Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Torasemide.Approved
RiociguatThe risk or severity of adverse effects can be increased when Torasemide is combined with Riociguat.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Torasemide is combined with Risperidone.Approved, Investigational
RitodrineRitodrine may increase the hypokalemic activities of Torasemide.Approved, Investigational
RituximabTorasemide may increase the hypotensive activities of Rituximab.Approved
RocuroniumTorasemide may decrease the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the diuretic activities of Torasemide.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Torasemide.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Torasemide.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Torasemide.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Torasemide.Approved
SabarubicinThe risk or severity of adverse effects can be increased when Torasemide is combined with Sabarubicin.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Torasemide.Approved
SafrazineSafrazine may increase the hypotensive activities of Torasemide.Withdrawn
SalbutamolSalbutamol may increase the hypokalemic activities of Torasemide.Approved, Vet Approved
SalicylamideSalicylamide may decrease the diuretic activities of Torasemide.Approved
Salicylic acidSalicylic acid may decrease the diuretic activities of Torasemide.Approved, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Torasemide.Approved
SalsalateSalsalate may decrease the diuretic activities of Torasemide.Approved
SaprisartanTorasemide may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Torasemide.Approved
SecobarbitalThe metabolism of Torasemide can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Torasemide.Approved, Investigational, Vet Approved
SelexipagTorasemide may increase the hypotensive activities of Selexipag.Approved
SemapimodSemapimod may decrease the diuretic activities of Torasemide.Investigational
SeratrodastSeratrodast may decrease the diuretic activities of Torasemide.Approved
SerrapeptaseSerrapeptase may decrease the diuretic activities of Torasemide.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Torasemide.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Torasemide.Approved, Investigational
SisomicinThe risk or severity of adverse effects can be increased when Torasemide is combined with Sisomicin.Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Torasemide.Approved, Investigational
SitaxentanTorasemide may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Torasemide.Approved
Sodium phosphateTorasemide may increase the nephrotoxic activities of Sodium phosphate.Approved
SorafenibThe metabolism of Torasemide can be decreased when combined with Sorafenib.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Torasemide.Investigational
SotalolThe risk or severity of adverse effects can be increased when Torasemide is combined with Sotalol.Approved
SP1049CThe risk or severity of adverse effects can be increased when Torasemide is combined with SP1049C.Investigational
SpectinomycinThe risk or severity of adverse effects can be increased when Torasemide is combined with Spectinomycin.Approved, Investigational, Vet Approved
SpiraprilTorasemide may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Torasemide is combined with Spironolactone.Approved
SRT501SRT501 may decrease the diuretic activities of Torasemide.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Torasemide.Approved, Investigational
StreptomycinThe risk or severity of adverse effects can be increased when Torasemide is combined with Streptomycin.Approved, Vet Approved
StreptozocinThe risk or severity of adverse effects can be increased when Torasemide is combined with Streptozocin.Approved
SuccinylcholineTorasemide may decrease the neuromuscular blocking activities of Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Torasemide.Approved, Investigational
SulfadiazineThe metabolism of Torasemide can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Torasemide can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineSulfasalazine may decrease the diuretic activities of Torasemide.Approved
SulfisoxazoleThe metabolism of Torasemide can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may decrease the diuretic activities of Torasemide.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Torasemide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Torasemide is combined with Sulpiride.Approved, Investigational
SuprofenSuprofen may decrease the diuretic activities of Torasemide.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the diuretic activities of Torasemide.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Torasemide.Approved, Investigational
TalinololTorasemide may increase the hypotensive activities of Talinolol.Investigational
TamoxifenThe metabolism of Torasemide can be decreased when combined with Tamoxifen.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Torasemide.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Torasemide.Approved
TarenflurbilTarenflurbil may decrease the diuretic activities of Torasemide.Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Torasemide is combined with Telmisartan.Approved, Investigational
TemocaprilTorasemide may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapTenidap may decrease the diuretic activities of Torasemide.Experimental
TenoxicamTenoxicam may decrease the diuretic activities of Torasemide.Approved
TepoxalinTepoxalin may decrease the diuretic activities of Torasemide.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Torasemide is combined with Terazosin.Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Torasemide.Approved
TeriflunomideTeriflunomide may decrease the diuretic activities of Torasemide.Approved
TerlipressinTorasemide may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineTorasemide may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Torasemide.Approved, Investigational, Withdrawn
TheodrenalineTorasemide may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThiamylal may increase the hypotensive activities of Torasemide.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Torasemide.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Torasemide.Approved, Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the diuretic activities of Torasemide.Approved
TiboloneTorasemide may increase the hypotensive activities of Tibolone.Approved, Investigational
TicagrelorThe metabolism of Torasemide can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Torasemide can be decreased when combined with Ticlopidine.Approved
TicrynafenTorasemide may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Torasemide.Experimental
TimololThe risk or severity of adverse effects can be increased when Torasemide is combined with Timolol.Approved
TinoridineTinoridine may decrease the diuretic activities of Torasemide.Investigational
TixocortolTixocortol may increase the hypokalemic activities of Torasemide.Approved
TizanidineThe risk or severity of adverse effects can be increased when Torasemide is combined with Tizanidine.Approved
TobramycinThe risk or severity of adverse effects can be increased when Torasemide is combined with Tobramycin.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Torasemide.Approved
TolazolineTorasemide may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Torasemide can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Torasemide.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the diuretic activities of Torasemide.Approved
TolmetinTolmetin may decrease the diuretic activities of Torasemide.Approved
TolonidineTorasemide may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Torasemide.Approved
TopiramateTorasemide may increase the hypokalemic activities of Topiramate.Approved
TopiroxostatThe metabolism of Torasemide can be decreased when combined with Topiroxostat.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Torasemide.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Torasemide is combined with Trandolapril.Approved
TranilastTranilast may decrease the diuretic activities of Torasemide.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Torasemide.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Torasemide.Approved
TravoprostTorasemide may increase the hypotensive activities of Travoprost.Approved
TreprostinilTorasemide may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Torasemide.Approved, Investigational, Nutraceutical
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Torasemide.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Torasemide is combined with Triamterene.Approved
TribenosideTribenoside may decrease the diuretic activities of Torasemide.Experimental
TrichlormethiazideTorasemide may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Torasemide.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Torasemide.Approved, Investigational
TrimethoprimThe metabolism of Torasemide can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptolideTriptolide may decrease the diuretic activities of Torasemide.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Torasemide.Investigational, Withdrawn
Trolamine salicylateTrolamine salicylate may decrease the diuretic activities of Torasemide.Approved
TubocurarineTorasemide may decrease the neuromuscular blocking activities of Tubocurarine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Torasemide.Approved, Investigational
UlobetasolUlobetasol may increase the hypokalemic activities of Torasemide.Approved
UnoprostoneTorasemide may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Torasemide.Investigational
ValdecoxibValdecoxib may decrease the diuretic activities of Torasemide.Investigational, Withdrawn
Valproic AcidThe metabolism of Torasemide can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinThe risk or severity of adverse effects can be increased when Torasemide is combined with Valrubicin.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Torasemide.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Torasemide.Approved
VecuroniumTorasemide may decrease the neuromuscular blocking activities of Vecuronium.Approved
VerapamilThe risk or severity of adverse effects can be increased when Torasemide is combined with Verapamil.Approved
VilanterolVilanterol may increase the hypokalemic activities of Torasemide.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Torasemide.Approved, Investigational
VincamineTorasemide may increase the hypotensive activities of Vincamine.Experimental
VinpocetineTorasemide may increase the hypotensive activities of Vinpocetine.Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Torasemide.Approved, Investigational
VoriconazoleThe metabolism of Torasemide can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Torasemide.Approved
XipamideTorasemide may increase the hypotensive activities of Xipamide.Experimental
XylometazolineTorasemide may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Torasemide.Approved, Vet Approved
ZafirlukastThe metabolism of Torasemide can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenZaltoprofen may decrease the diuretic activities of Torasemide.Approved, Investigational
ZileutonZileuton may decrease the diuretic activities of Torasemide.Approved, Investigational, Withdrawn
ZofenoprilTorasemide may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracZomepirac may decrease the diuretic activities of Torasemide.Withdrawn
Zoptarelin doxorubicinThe risk or severity of adverse effects can be increased when Torasemide is combined with Zoptarelin doxorubicin.Investigational
ZorubicinThe risk or severity of adverse effects can be increased when Torasemide is combined with Zorubicin.Experimental
Food Interactions
Not Available

References

Synthesis Reference

Fritz Topfmeier, Gustav Lettenbauer, "Process for the preparation of a stable modification of torasemide." U.S. Patent USRE0345806, issued June, 1975.

USRE0345806
General References
  1. Dunn CJ, Fitton A, Brogden RN: Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs. 1995 Jan;49(1):121-42. [PubMed:7705212]
  2. Authors unspecified: FDA approved new drug bulletin: torsemide (Demadex), trimetrexate glucuronate (neuTrexin). RN. 1994 May;57(5):53-6. [PubMed:8197389]
External Links
Human Metabolome Database
HMDB14359
KEGG Drug
D00382
PubChem Compound
41781
PubChem Substance
46504760
ChemSpider
38123
BindingDB
64107
ChEBI
9637
ChEMBL
CHEMBL1148
Therapeutic Targets Database
DAP000745
PharmGKB
PA451733
RxList
RxList Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Torasemide
ATC Codes
C03CA04 — Torasemide
MSDS
Download (110 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedNot AvailableTo Determine Bioequivalence Under Fasting Conditions1
1CompletedBasic ScienceDrug Biotransformation / Membrane Transport1
1CompletedBasic ScienceGenotype-related Drug Metabolism1
1CompletedTreatmentType 2 Diabetes Mellitus1
1RecruitingTreatmentChronic Kidney Disease (CKD) / Congestive Heart Failure (CHF)1
1TerminatedTreatmentHeart Failure, Unspecified / Impaired Renal Function1
2RecruitingPreventionPreeclampsia1
2, 3CompletedTreatmentHeart Failure, Unspecified1
2, 3Not Yet RecruitingHealth Services ResearchAcute Heart Failure (AHF)1
4CompletedTreatmentHypertensive2
4CompletedTreatmentRight Heart Failure / Tricuspid valve incompetence1
4Not Yet RecruitingTreatmentHeart Failure, Unspecified1
4RecruitingTreatmentHeart Failure, Unspecified1
4Unknown StatusTreatmentArterial Hypertension / Chronic Heart Failure (CHF)1
Not AvailableCompletedTreatmentEdema2
Not AvailableNot Yet RecruitingTreatmentHeart Failure, Unspecified1
Not AvailableTerminatedDiagnosticAcute Decompensated Heart Failure (ADHF)1

Pharmacoeconomics

Manufacturers
  • Hoffmann la roche inc
  • Bedford laboratories
  • Luitpold pharmaceuticals inc
  • Meda pharmaceuticals inc
  • Apotex inc etobicoke site
  • Aurobindo pharma ltd
  • Hetero drugs ltd
  • Par pharmaceutical inc
  • Pliva pharmaceutical industry inc
  • Roxane laboratories inc
  • Sun pharmaceutical industries ltd
  • Teva pharmaceuticals usa inc
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg/1
TabletOral100 mg/1
TabletOral20 mg/1
TabletOral5 mg/1
LiquidIntravenous10 mg
TabletOral100 mg
TabletOral10 mg
TabletOral20 mg
TabletOral5 mg
InjectionIntravenous10 mg/mL
Injection, solutionIntravenous10 mg/mL
Prices
Unit descriptionCostUnit
Demadex 100 mg tablet5.69USD tablet
Torsemide 100 mg tablet3.16USD tablet
Demadex 20 mg tablet1.59USD tablet
Demadex 10 mg tablet1.39USD tablet
Demadex 5 mg tablet1.28USD tablet
Torsemide 20 mg tablet0.85USD tablet
Torsemide 10 mg tablet0.73USD tablet
Torsemide 5 mg tablet0.66USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)164-164 °CNot Available
water solubilityWater solubleNot Available
logP2.3Not Available
pKa7.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0596 mg/mLALOGPS
logP1.76ALOGPS
logP1.86ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)5.92ChemAxon
pKa (Strongest Basic)4.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area100.19 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity91.89 m3·mol-1ChemAxon
Polarizability36.15 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier+0.6871
Caco-2 permeable-0.5374
P-glycoprotein substrateNon-substrate0.799
P-glycoprotein inhibitor INon-inhibitor0.7695
P-glycoprotein inhibitor IINon-inhibitor0.8232
Renal organic cation transporterNon-inhibitor0.9185
CYP450 2C9 substrateSubstrate0.6049
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7558
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.6692
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.5905
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6324
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8366
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.8740 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9854
hERG inhibition (predictor II)Non-inhibitor0.8668
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03di-0090000000-bcaf4981571fb662df86
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03di-0090000000-00cc7369c05298ea1c97
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03di-0490000000-60171fe07a2f255596e3
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-01ot-2950000000-359d6835f9bf703a0701
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000t-3910000000-a5ec65a6dbedfe7a30d3
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0564-6900000000-051171526b146f5d076c
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03di-0190000000-1b2efe76058c7bf06b4a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0091000000-548edfa45514c501788d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0090000000-d7326b2b38380cd06e26
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0490000000-b9f43c4768937947d77f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-0940000000-7b7084526f7c13bf6443
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00lr-0910000000-81aa8c9ff5d9a3cd3c10
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0159-0900000000-87860a9931a8414432cf
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-1590000000-1b7d966c20cec1451f6c
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0490000000-bd8b6af3fe8d0f10e117
MS/MS Spectrum - , positiveLC-MS/MSsplash10-02ai-2940000000-5beb0e7e25d393903803
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0390000000-314819093d7d5a1f48f4

Taxonomy

Description
This compound belongs to the class of organic compounds known as pyridinesulfonamides. These are heterocyclic compounds containing a pyridine ring substituted by one or more sulfonamide groups.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Pyridinesulfonamides
Direct Parent
Pyridinesulfonamides
Alternative Parents
Toluenes / Sulfonylureas / Dihydropyridines / Secondary ketimines / Organosulfonic acids and derivatives / Heteroaromatic compounds / Aminosulfonyl compounds / Propargyl-type 1,3-dipolar organic compounds / Carboximidic acids and derivatives / Azacyclic compounds
show 4 more
Substituents
Pyridine-3-sulfonamide / Dihydropyridine / Toluene / Sulfonylurea / Monocyclic benzene moiety / Hydropyridine / Benzenoid / Secondary ketimine / Heteroaromatic compound / Organic sulfonic acid or derivatives
show 16 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
secondary amino compound, aminopyridine, N-sulfonylurea (CHEBI:9637)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A1
Uniprot ID
Q13621
Uniprot Name
Solute carrier family 12 member 1
Molecular Weight
121449.13 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Vormfelde SV, Sehrt D, Toliat MR, Schirmer M, Meineke I, Tzvetkov M, Nurnberg P, Brockmoller J: Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9. Epub 2007 Apr 25. [PubMed:17460608]
  3. Fortuno A, Muniz P, Ravassa S, Rodriguez JA, Fortuno MA, Zalba G, Diez J: Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension. 1999 Jul;34(1):138-43. [PubMed:10406837]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:34